Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 10/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.49 |
| ▸ | GCGR | P47871 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 6/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221938 | 0.79 | KDM4E (0.60) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL22394678 | 0.77 | MAPK14 (0.47) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL8509175 | 0.77 | KDM4E (0.59) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL13740750 | 0.73 | KDM4E (0.58) | MAPK14KDM4EHPGDALDH1A1MAPT | |
| SCHEMBL134658 | 0.72 | DYRK1A (0.60) | — | |
| SCHEMBL30559511 | 0.72 | DYRK1A (0.60) | — | |
| SCHEMBL13740640 | 0.71 | MAPK14 (0.53) | MAPK14ADORA2AALDH1A1MAPT | |
| SCHEMBL13740667 | 0.71 | NOTUM (0.54) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4097414 | 0.71 | MAPK14 (0.60) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL13740516 | 0.71 | MAPK14 (0.55) | MAPK14ADORA2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | MAPK13 99/4885MAPK12 111/4885MAPK11 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.